• No results found

Cover Page The handle http://hdl.handle.net/1887/39789 holds various files of this Leiden University dissertation

N/A
N/A
Protected

Academic year: 2021

Share "Cover Page The handle http://hdl.handle.net/1887/39789 holds various files of this Leiden University dissertation"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The handle http://hdl.handle.net/1887/39789 holds various files of this Leiden University dissertation

Author: Engels, Charla Chábeli

Title: Integrating clinicopathological and molecular data in the breast cancer patient : towards precision medicine

Issue Date: 2016-05-19

(2)

Stellingen

behorend bij het proefschrift

Integrating clinicopathological and molecular data in the breast cancer patient Towards precision medicine

1. Immunoediting generates breast tumors capable of immune escape, which leads to cancer progression and worse clinical outcomes (This thesis)

2. Breast tumor IGF1 receptor status has proven a promising marker for the treatment of hor- mone receptor positive breast cancer patients. Time will tell whether it will also be of great value in the aging cancer population due to the mild adverse events of metformin treatment (This thesis)

3. The dual role of HIF-1 in both cancer and aging may explain why the greatest risk of cancer is age (This thesis)

4. TNM staging does not provide an optimal prognostic and treatment decision-making-model and therefore should be complemented with tumor (bio)-markers and patient characteris- tics to achieve personalized treatment (This thesis)

5. To provide the most adequate breast cancer treatment per individual, the practitioner should loosen the reins on strict guidelines, moving further away from the “one-size-fits-all”

concept and strive for tailored treatment

6. It is argued that an inventory of feedback and crosstalk circuits between signaling pathways will be instrumental in finding the right drug combinations for each individual patient. Our lack of understanding of the way in which signaling networks interconnect represents a critical missing link in realizing the ultimate goal of personalized medicine (Bernards R, Cell.

2012 Oct 26;151(3):465-8)

7. If age-related metabolic changes are an early driver of tumorigenesis, molecules that prevent and reverse metabolic aging may be useful as cancer therapies. Given the key role of sirtuins in tumorigenesis, it is feasible that lifestyle interventions and small molecules that activate sirtuins could induce a youthful metabolic state and serve to prevent and treat cancer (Wu LE, Cancer Cell. 2014 Jan 13;25(1):12-9)

8. Surgical oncology, medical oncology and radiation oncology, also known as “the big three”

players in (breast) cancer treatment will soon become “the big four”, as the interventional radiologist is progressively becoming the treating physician of choice for patients who are less suitable candidates for surgery

9. The good thing about science is that it’s true whether or not you believe in it (Neill deGrasse Tyson, Twitter, 2013)

10. In science we abide by: ‘Quod gratis asseritur, gratis negatur‘(Anonymous)

11. Het hospitaal is een noodzakelijk kwaad, hoe meer men er buiten houdt hoe beter het eraan toe gaat (Dr. C.J.H.Engels)

12. No guts, no glory (Major Gen. Frederick C. Blesse, fighter tactics book US Airforce, 1955) Charla C. Engels Leiden, 19 mei 2016

Referenties

GERELATEERDE DOCUMENTEN

subtypes in postmenopausal, hormone receptor positive breast cancer patients treated with adjuvant endocrine therapy: A Dutch TEAM Study

The FOCUS project consists of four domains; analysis of a large observational cohort of elderly patients; age- specific analyses of clinical trial data; a prospective study

Title: Integrating clinicopathological and molecular data in the breast cancer patient : towards precision medicine. Issue

By constructing an apoptotic-proliferative tumor subtyping model, we demonstrated that the combination of the expression rates of all relevant apoptotic and proliferative

The defined tumor immune subtypes were in ascending order from high immune susceptibility to low immune susceptibility: (1) CTL are able to recognize tumor-associated antigens

classical HLA-I (HCA2 and HC10) and non-classical HLA-E and HLA-G expression and Treg (FoxP3), CTL (CD8) and NK cell (PEN5) infiltration in the tumor material  15. As described by

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor- positive breast cancer patients treated with adjuvant endocrine therapy:

In our study, the distribution of the molecular intrinsic breast tumor subtypes in this older breast cancer population showed a higher prevalence of the assumed more in- dolent